Upcoming event

Tags

Abiraterone, abiraterone acetate, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, apalutamide, ARCHES, Article of the Month, artificial intelligence, ASCO GU21, ASCO GU22, ASCO2026, ASCO21, ASCO26, AUA21, BHC80, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, CAPItello-281, capivasertib, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, darolutamide, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, high-risk prostate cancer, homologous recombination repair, hormone-sensitive, HORRAD, HRQL, HRR-deficient mCSPC, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, locally advanced prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, mCSPC, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, metastatic castration-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, PEACE-1 trial, pelvic lymph node dissection, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, prednisone, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, Prognosis, Prognostic model, Prostasomes, prostate cancer, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PROTEUS study, PSA, PSA flare, PSA kinetics, PSA screening, PSMA PET/CT, PTEN, PTEN deficiency, Quality of life, Radiation therapy, Radical prostatectomy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Summer read, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, TALAPRO-3 study, talazoparib, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, UROonco25, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis

ASCO GU26, February 2026

Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial

Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer

ASCO GU26, February 2026

Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC

ASCO GU26, February 2026

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

The LANCET Oncology, February 2026

Trial design and objectives for patients with prostate cancer: Recommendations from the Prostate Cancer Working Group 4

Journal of Clinical Oncology, February 2026

Primary noncontrast magnetic resonance imaging for prostate cancer screening: A randomized clinical trial (PROSA)

European Urology, December 2025

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

Annals of Oncology, January 2026

Active monitoring, surgery, and radiotherapy for cribriform-positive and cribriform-negative prostate cancer: A secondary analysis of the PROTECT randomised clinical trial

JAMA Oncology, October 2025

Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)

ESMO25, October 2025

3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial

ESMO25, October 2025

Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

ESMO25, October 2025

PreviousNext